急性胸痛就诊的医疗费用负担
该研究为澳大利亚维多利亚州全州人群队列,纳入2015年1月1日至2019年6月30日连续成年急性胸痛救护车就诊患者,个体链接急诊与住院数据,按病例组合 funding 方法估算直接医疗费用(调整至2020–2021财年澳元)。241627次救护车胸痛就诊中,平均每次发作费用6284澳元,年总费用估计3.374亿澳元(人均每年68澳元);年总费用从2015年3.105亿澳元增至2019年3.845亿澳元,而平均每次发作费用保持稳定。心血管病因(占25%)最贵(平均11523澳元,年总1.487亿澳元),非特异性疼痛诊断(占49%)最便宜(平均3836澳元,年总9340万澳元)。按ECAMM评分判定的低危患者占队列31%–57%,年总费用6060万–1.354亿澳元(取决于所用评分界值),作者认为需改善胸痛诊疗路径的成本效益。
要点
- 241627次救护车胸痛就诊,平均每次发作费用6284澳元,年总费用3.374亿澳元(人均每年68澳元)。
- 年总费用从2015年3.105亿澳元增至2019年3.845亿澳元,平均每次发作费用保持稳定。
- 心血管病因占25%就诊、最贵:平均11523澳元、年总1.487亿澳元;非特异性疼痛占49%、最便宜:平均3836澳元、年总9340万澳元。
- ECAMM评分判定的低危患者占队列31%–57%,年总费用6060万–1.354亿澳元(取决于评分界值)。
- 作者认为这些数据提示需改善胸痛诊疗路径的成本效益。
适用人群与场景
- 澳大利亚维多利亚州2015年1月1日至2019年6月30日连续成年急性胸痛救护车就诊患者,个体链接急诊与住院入院数据。
诊断标准与关键阈值
- 低危判定采用Early Chest pain Admission, Myocardial infarction, and Mortality(ECAMM)评分,低危患者占队列31%–57%(取决于所用评分界值)。
研究设计与关键结果
- 研究类型:全州人群队列研究;241627次救护车胸痛就诊;平均每次发作费用6284澳元,年总费用3.374亿澳元(人均每年68澳元)。
- 年总费用2015年3.105亿澳元 vs 2019年3.845亿澳元,期间增加,平均每次发作费用保持稳定。
- 心血管病因占25%就诊,平均11523澳元,年总1.487亿澳元,为最贵类别。
- 非特异性疼痛诊断占49%就诊,平均3836澳元,年总9340万澳元,为最便宜类别。
- ECAMM评分低危患者占31%–57%,年总费用6060万–1.354亿澳元(取决于评分界值)。
证据类型、等级与局限
- 证据类型:全州人群队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,年总费用上升且相当比例费用负担来自低危患者和非特异性疼痛,这些数据提示需改善胸痛诊疗路径的成本效益。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: This study aimed to estimate the direct healthcare cost burden of acute chest pain attendances presenting to ambulance in Victoria, Australia, and to identify key cost drivers especially among low-risk patients.
METHODS: State-wide population-based cohort study of consecutive adult patients attended by ambulance for acute chest pain with individual linkage to emergency and hospital admission data in Victoria, Australia (1 January 2015-30 June 2019). Direct healthcare costs, adjusted for inflation to 2020-2021 ($A), were estimated for each component of care using a casemix funding method.
RESULTS: From 241 627 ambulance attendances for chest pain during the study period, mean chest pain episode cost was $6284, and total annual costs were estimated at $337.4 million ($68 per capita per annum). Total annual costs increased across the period ($310.5 million in 2015 vs $384.5 million in 2019), while mean episode costs remained stable. Cardiovascular conditions (25% of presentations) were the most expensive (mean $11 523, total annual $148.7 million), while a non-specific pain diagnosis (49% of presentations) was the least expensive (mean $3836, total annual $93.4 million). Patients classified as being at low risk of myocardial infarction, mortality or hospital admission (Early Chest pain Admission, Myocardial infarction, and Mortality (ECAMM) score) represented 31%-57% of the cohort, with total annual costs estimated at $60.6 million-$135.4 million, depending on the score cut-off used.
CONCLUSIONS: Total annual costs for acute chest pain presentations are increasing, and a significant proportion of the cost burden relates to low-risk patients and non-specific pain. These data highlight the need to improve the cost-efficiency of chest pain care pathways.
参考来源
- Dawson L, Nehme E, Nehme Z, et al. Healthcare cost burden of acute chest pain presentations. Emerg Med J. 2023. PMID: 36918268. doi:10.1136/emermed-2022-212674
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。